Dr. Bryan Patenaude, ScD is an economist and Assistant Professor of Economic Evaluation in the Department of International Health at the Johns Hopkins Bloomberg School of Public Health. His research interests broadly include assessing the strength, sustainability, and efficiency of health financing, integrating equity and behavioral economics into the economic analysis of health policy, modeling patient preferences for healthcare, and understanding the medium and long-term impact of health investments on non-health sectors. Through this work he has extensive experience with modeling the costs and cost-effectiveness of public health interventions including providing future projections of the costs and economic impact of infection prevention policy and treatment programs. Bryan also has served as the senior economist to the USAID Global Health Bureau’s HIV/AIDS program where he developed methods and guidelines for assessing the efficiency of different strategies of outreach, testing, and treatment in key-populations. An important area of Bryan's research includes estimating the economic impact of vaccines globally as well as the economic burden of infectious diseases such as HIV, TB, and Malaria in Low and Middle-Income countries. At Johns Hopkins, he is a member of the International Vaccine Access Center (IVAC) and the principal investigator for the Bill & Melinda Gates Foundation funded Vaccine Economics Research for Sustainability and Equity (VERSE) project, which seeks to quantify the economic cost-of-illness and immunization coverage equity associated with vaccine-preventable diseases. The return-on-investment estimates he has generated from work under the Decade of Vaccine Economics (DOVE-IV) project have been used by GAVI, the vaccine alliance for their investment case and replenishment meetings as well as by the WHO, UNICEF, and USAID. Bryan holds a BA in International Economics from Boston College, an MA in Global Development Economics from Boston University and an ScD in Health Economics from the Harvard T.H. Chan School of Public Health.
Areas of Expertise (10)
Health Systems Strengthening
Sustainable Health Financing
Forbes 30 Under 30 (professional)
Excellence in Teaching – Economic Evaluation IV (professional)
2020 Johns Hopkins Bloomberg School of Public Health
Boston College: BA, International Economics 2012
Boston University: MA, Global Development Economics 2014
Harvard T.H. Chan School of Public Health: ScD, Health Economics 2017
- Sustainable Finance & Economics Advisory Committee : Member
Media Appearances (3)
Economic benefits of vaccination programmes vastly outweigh costs
New Scientist online
The costs of vaccination programmes are vastly outweighed by the economic benefits of reducing illness, disability and premature death, a modelling study has found. “We hope these numbers can allow vaccines to be seen as investments rather than expenses,” says Bryan Patenaude at Johns Hopkins University in Baltimore, Maryland, who led the study.
Johns Hopkins study finds immunization programs pay off in long run
The goal of the research was to figure out how much money a country’s economy loses when kids aren’t vaccinated for preventable diseases, and compare that number to how much it costs to give the vaccines. “This allows us to compare things in an apples-to-apples way,” said Bryan Patenaude, the study’s senior author and assistant professor in the school’s department of international health.
Former Summer Fellow Bryan Patenaude Makes Forbes “30 Under 30” List
BU Today online
Bryan Patenaude, a 2013 Graduate Summer Fellow at the Frederick S. Pardee Center for the Study of the Longer-Range Future, recently made the 2020 Forbes “30 Under 30” List in the healthcare category.
Featured Articles (5)
How much does it cost to measure immunity? A costing analysis of a measles and rubella serosurvey in southern ZambiaPLOS ONE
Serosurveys are a valuable surveillance tool because they provide a more direct measure of population immunity to infectious diseases, such as measles and rubella, than vaccination coverage estimates. However, there is concern that serological surveys are costly. We adapted a framework to capture the costs associated with conducting a serosurvey in Zambia.
The economic burden of measles in children under five in UgandaVaccine: X
There is very limited evidence about the economic cost of measles in low-income countries. We estimated the cost of treating measles in Uganda from a societal perspective.
Costs of Immunization Programs for 10 Vaccines in 94 Low- and Middle-Income Countries From 2011 to 2030Value in Health
Understanding the level of investment needed for the 2021-2030 decade is important as the global community faces the next strategic period for vaccines and immunization programs. To assist with this goal, we estimated the aggregate costs of immunization programs for ten vaccines in 94 low- and middle-income countries from 2011 to 2030.
The economic burden of measles in children under five in BangladeshBMC Health Services Research
This study estimated the economic cost of treating measles in children under-5 in Bangladesh from the caregiver, government, and societal perspectives.
Return On Investment From Immunization Against 10 Pathogens In 94 Low- And Middle-Income Countries, 2011–30Health Affairs
Estimating the value of global investment in immunization programs is critical to helping decision makers plan and mobilize immunization programs and allocate resources required to realize their full benefits. We estimated economic benefits using cost-of-illness and value-of-a-statistical-life approaches and combined this estimation with immunization program costs to derive the return on investment from immunization programs against ten pathogens for ninety-four low- and middle-income countries for the period 2011–30.